Plain-English translation of NCT02947945 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Asthma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to treat EGPA, a rare disease where your immune system attacks blood vessels and organs in your body. You would receive this medication as an injection into your vein every four weeks for seven weeks, while continuing to take your current EGPA medicines. The study wants to see if the treatment helps reduce symptoms and allows you to use lower doses of steroid medications.
EGPA is a serious disease that currently requires strong steroid and immune-suppressing medications, which can have significant side effects. This trial is testing whether this new treatment can work alongside your existing medicines to control the disease better and potentially let you reduce your steroid dose.
You likely qualify if…
You likely don't qualify if…
You would visit the study clinic 11 times over 44 weeks (about 10 months). At your first visit and every four weeks after that, you would receive an injection of the medication into your vein, along with blood tests and check-ups. Study staff would also call you every two weeks to see how you're doing and ask about your symptoms and medications. You would continue taking all your regular EGPA medicines, though your doctor may try to reduce your steroid dose if you improve.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States